PMID- 26844011
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20221207
IS  - 2163-8306 (Electronic)
IS  - 2163-8306 (Linking)
VI  - 5
IP  - 1
DP  - 2016 Jan
TI  - Weight-HbA1c-insulin-glucose model for describing disease progression of type 2 
      diabetes.
PG  - 11-9
LID - 10.1002/psp4.12051 [doi]
AB  - A previous semi-mechanistic model described changes in fasting serum insulin 
      (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients 
      with type 2 diabetic mellitus (T2DM) by modeling insulin sensitivity and beta-cell 
      function. It was later suggested that change in body weight could affect insulin 
      sensitivity, which this study evaluated in a population model to describe the 
      disease progression of T2DM. Nonlinear mixed effects modeling was performed on 
      data from 181 obese patients with newly diagnosed T2DM managed with diet and 
      exercise for 67 weeks. Baseline beta-cell function and insulin sensitivity were 61% 
      and 25% of normal, respectively. Management with diet and exercise (mean change 
      in body weight = -4.1 kg) was associated with an increase of insulin sensitivity 
      (30.1%) at the end of the study. Changes in insulin sensitivity were associated 
      with a decrease of FPG (range, 7.8-7.3 mmol/L) and HbA1c (6.7-6.4%). Weight 
      change as an effector on insulin sensitivity was successfully evaluated in a 
      semi-mechanistic population model.
FAU - Choy, S
AU  - Choy S
AD  - Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden.
FAU - Kjellsson, M C
AU  - Kjellsson MC
AD  - Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden.
FAU - Karlsson, M O
AU  - Karlsson MO
AD  - Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden.
FAU - de Winter, W
AU  - de Winter W
AD  - Janssen Prevention Center Janssen Pharmaceutical Companies of Johnson & Johnson 
      Leiden The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20151216
PL  - United States
TA  - CPT Pharmacometrics Syst Pharmacol
JT  - CPT: pharmacometrics & systems pharmacology
JID - 101580011
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Algorithms
MH  - Blood Glucose/*metabolism
MH  - Body Weight
MH  - Diabetes Mellitus, Type 2/metabolism/*therapy
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Female
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Insulin/*blood
MH  - Male
MH  - Middle Aged
MH  - *Models, Biological
MH  - Obesity/blood/*complications/metabolism
MH  - Young Adult
PMC - PMC4728293
EDAT- 2016/02/05 06:00
MHDA- 2016/02/05 06:01
PMCR- 2016/01/01
CRDT- 2016/02/05 06:00
PHST- 2015/09/24 00:00 [received]
PHST- 2015/11/16 00:00 [accepted]
PHST- 2016/02/05 06:00 [entrez]
PHST- 2016/02/05 06:00 [pubmed]
PHST- 2016/02/05 06:01 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - PSP412051 [pii]
AID - 10.1002/psp4.12051 [doi]
PST - ppublish
SO  - CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):11-9. doi: 10.1002/psp4.12051. 
      Epub 2015 Dec 16.